In the early life of Aqtual, CEO meant chief executive, computational biologist, pitch rehearser and part-time contractor. Diana Abdueva wrote in 2020 that she had recently learned masking, rolling and cutting paint. The day before, she had swapped drop-ceiling tiles. Caulking was next. Her new lab was beginning to look presentable, she joked, and so was the investor pitch she practiced while working.
It is a useful scene because it shrinks the distance between frontier science and a hardware-store run. The company Abdueva was assembling would attempt to read a layer of biological information that ordinary methods often leave behind. But before a team could do that at scale, somebody had to make the room function. Abdueva did not narrate the work as a founding myth. She treated it as the week’s task list.
That blend of abstraction and practicality has followed her for two decades. She studied applied physics at the Moscow Institute of Physics and Technology, then entered the University of Southern California, where her graduate training combined applied mathematics and computational biology. Simon Tavaré was her PhD adviser; her training also included a master’s in applied mathematics and another in computational biology. The mix matters: biology provides the mess; mathematics provides ways to distinguish a real signal from the noise around it.
A career built around bad signals
Abdueva’s early papers were less glamorous than the promise now attached to liquid biopsy, and more revealing. A 2006 paper examined the nonlinear behavior of GeneChip arrays. Another compared two Affymetrix platforms. The problem was measurement itself: how does a tool behave, where does it saturate, and which apparent differences belong to biology rather than the instrument?
This is the recurring problem in her career. The body produces an extravagant amount of data, but a useful answer depends on knowing what the measurement can and cannot support. After research work connected to USC and Children’s Hospital Los Angeles, Abdueva moved through Affymetrix, Veracyte, Verinata Health, Ion Torrent and Guardant Health. Each company occupied a different point in the conversion of molecular information into a product. Her titles moved through biostatistics, bioinformatics and research leadership. Her patent record moved with her.
At Verinata, she worked on methods for improving the detection of copy-number variation. At Guardant, she became an inventor on methods for fragmentome profiling and analysis of nucleic-acid molecules. A single-inventor filing from that period described a way to study cell-free DNA at a global scale, looking at the shape and distribution of fragments rather than relying only on the letters of the genetic sequence. The idea pushed attention toward the physical traces carried by DNA fragments themselves.
“We are complex organisms that work beautifully for many years.”Diana Abdueva, 2024
The professional relationships lasted, too. Rich Rava, who appears with Abdueva on Verinata patents, became her Aqtual co-founder. A 2025 year-end note from Abdueva called working with him a daily privilege. That line offers a quiet correction to the lone-genius version of company building. Aqtual grew from accumulated methods and accumulated trust.
The information between the letters
Aqtual’s central proposition is that the sequence of DNA is not the only useful thing to read. DNA is packaged with proteins into chromatin, and the arrangement carries evidence about gene regulation. Some cell-free DNA circulating in blood comes attached to active chromatin. Capture the right fragments, quantify them and process the resulting signals, and a blood sample can reveal a more dynamic picture of activity across tissues.
The scale is easy to miss. Aqtual describes a catalog spanning more than 200,000 promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers and over one million transcription-factor binding sites. These are not five tidy data columns. They are a map of regulatory activity whose value depends on choosing the right landmarks and showing that the pattern repeats.
This is why Abdueva’s background looks less like a résumé and more like prerequisite reading. A founder without years inside diagnostic measurement might see a large dataset and assume the hard part is collection. Abdueva had spent her career confronting the next questions: Which artifacts travel with the platform? Which patterns are stable? Which can survive validation? What would make an elegant result usable?
Your edge may not be a secret insight. It may be twenty years of knowing which beautiful results will fail the next test.
Conviction takes longer than a pitch
Looking back in 2026, Abdueva discussed the early challenge of building a company around science that does not compress neatly. Her answer was not to flatten the material into a slogan. The right early partners, she said, were people willing to spend the time required to understand it and then help communicate it. In complex science, comprehension becomes a form of diligence.
Aqtual’s financing history reflects that longer clock. The company began around 2018 and filed in California in 2019. It emerged from stealth in 2023 with early research, a prospective study and a $16 million Series A. In 2024, work describing extraction of a regulatory active-chromatin footprint from cell-free DNA appeared in Communications Biology. In July 2025, Aqtual announced an oversubscribed $31 million Series B, joined by new and returning investors.
The round is a milestone, but the more interesting asset is the sequence underneath it: graduate work about measurement, years inside diagnostic systems, patent filings that treat DNA fragments as information-rich objects, a durable co-founder relationship, a lab built by hand, and a company that waited years before presenting itself broadly. Funding did not invent the thesis. It increased the number of tests the thesis could face.
A CEO who still thinks like a scientist
Abdueva’s public writing has the clipped rhythm of an operator. She praises teams by naming completed work. She uses jokes to puncture the ceremonial language around leadership. After one 2026 industry event, she wrote that returning to the Aqtual crew was the best part of the trip because that was where the work began again. At another moment, she described the oddness of seeing one platform travel to two scientific conferences with very different applications. The satisfaction was not that the company had told a platform story. It was that the experiments had begun to behave like one.
Her recognition has grown with the company. In 2026, the San Francisco Business Times included her among its Most Influential Women in Bay Area Business. She took her first PMWC stage that March. Aqtual added senior leaders in July. These are public signs that the job is changing from proving a method to building an organization capable of carrying it.
The people around the work show how deliberately that organization has been assembled. Aqtual’s public team brings together laboratory operations, assay development, data integrity, finance and biospecimen strategy. Its advisers include specialists in reimbursement, immunology, oncology and laboratory medicine. The 2025 round brought in Bold Capital and Bold Longevity Growth Fund alongside existing backers Genoa Ventures, Manta Ray Ventures and Yu Galaxy, plus a strategic diagnostics investor. It is a network designed around the gaps that appear after an experiment works: quality systems, clinical evidence, payment, partnerships and manufacturing discipline.
Abdueva’s own job has widened along the same path. The early technical founder could argue for the measurement. The later-stage CEO has to decide which proof belongs next, recruit the person capable of producing it, and preserve enough focus for the platform to become a product. Her public posts return repeatedly to the team, completed studies and the next conference rather than to founder mythology. When she writes about pride, the object is usually collective: a study completed, a scientific result presented, colleagues showing up, a new leader joining. The language is intense but concrete. Progress has a noun attached to it.
That habit may come from science, where a claim is only as useful as the evidence under it. It also suits a company whose central challenge is translation. Aqtual must translate fragments into patterns, patterns into validated findings, findings into a product, and a difficult platform into a reason for partners to stay engaged. Abdueva occupies every handoff. Her distinctive role is not merely having the original technical conviction. It is keeping the conviction intact as more people, more capital and more consequences gather around it.
Yet the paint-roller anecdote remains the better portrait. It captures a founder willing to cross layers: code and chemistry, lab and boardroom, technical detail and a legible pitch. Aqtual’s scientific bet is that a small tube contains a richer record than existing tools routinely capture. Abdueva’s career bet is similar. Pay closer attention. Improve the measurement. Do not discard difficult information merely because it is difficult to explain.
The room is finished now. The pitch has been practiced. The next work is harder to photograph: validation, repetition, translation and scale. Abdueva has spent twenty years preparing for precisely that kind of unglamorous difficulty.